Pharmaceuticals

MediLink Announces Global Clinical Trial Collaboration and Supply Agreement on YL201 Combination Therapy

SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announced a global clinical trial collaboration and supply agreement with Amgen Inc. Amgen will lead a global clinical study to evaluate the therapeutic poten...

2024-10-08 08:00 1355

Innovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic...

2024-10-08 08:00 1652

Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy

MELBOURNE, Australia, Oct. 8, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has approved the use of Illuccix® (kit for the preparation of68Ga-PSMA-11[1] injection) to select patients for...

2024-10-08 04:00 1630

The U.S. Fish and Wildlife Service Rejects Petition to List Long-Tailed Macaques Under the Endangered Species Act

WASHINGTON, Oct. 8, 2024 /PRNewswire/ -- On October 7, 2024, the U.S. Fish and Wildlife Service ("USFWS" or "the Service") declined to accept a petition filed by People for the Ethical Treatment of Animals (PETA) and other advocacy groups to list long-tailed macaque ("LTM") monkeys (Macaca fascic...

2024-10-08 03:31 1374

GBI Biomanufacturing and Allterum Therapeutics Announce Strategic Collaboration to Manufacture Therapeutic Antibody for Clinical Trials

PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ -- GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), andAllterum Therapeutics, a Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candi...

2024-10-08 00:00 1218

NTC Launches Imperial, the new eye drops product line on THE PATIENT'S SIDE

MILAN, Oct. 7, 2024 /PRNewswire/ -- NTC, an international pharmaceutical company headquartered inMilan, Italy, announced today to have embraced a strategic partnership with Silgan Dispensing Systems, a global leading supplier of dispensing solutions in healthcare to commercialize a set of new NTC...

2024-10-07 18:00 1033

Antengene to Present Results from Three Programs at the 2024 SITC Annual Meeting

SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...

2024-10-07 13:14 1794

TiumBio Announces First Patient Dosed in Phase 2 Clinical Trial of Oral Immuno-Oncology Drug TU2218

* TU2218 is a potentially first-in-class dual inhibitor targeting transforming growth factor beta receptor 1 (TGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) * The first patient with head and neck squamous cell carcinoma was dosed in the Phase 2a clinical trial of TU2218 *...

2024-10-04 20:00 1650

Clarivate in partnership with Abiquifi Announces Annual Summit LATAM Agenda

Top industry leaders to explore AI, data, strategic partnerships, and innovation opportunities inLatin America at premier Life Sciences event LONDON, Oct. 4, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, today announced the full agenda ...

2024-10-04 15:00 1794

Sirnaomics Has Been Subscribed for 17,527,696 Subscription Shares, New Capital Injection to Promote Business Growth and Development

HONG KONG, GERMANTOWN, Md., and SUZHOU, China,, Oct. 4, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", together with its subsidiaries, the "Group" or " Sirnaomics"; stock code: 2257.HK), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutic...

2024-10-04 13:03 5538

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase1b/2 clinical trial SEONGNAM, South Korea, Oct. 4, 2024 /PRNewswire/ -- ABL Bio (CEO Sang Hoon Lee ), a company specializing in bispecific antibodies, today announced that it has entered into a clinical tria...

2024-10-04 12:40 2361

First Patient Dosed in Phase II 'CA-NINE' Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery

MELBOURNE, Australia, Oct. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix's first-in-class investigational PET[1] agent, TLX250-CDx (89Zr-girentu...

2024-10-04 04:00 2852

IBC launches RadSep, Inc.: Best-in-class, highly selective separations using Molecular Recognition Technology™ (MRT™) for production of critical radioisotopes essential to cancer therapies

* Best-in-class, highly selective separations technology for the radiopharmaceuticals industry * Exhibitor at the European Association of Nuclear Medicine (EANM) Congress in Hamburg, Germany 20-23 October 2024 at Booth S14 (Exhibition Hall 3) * Over 36 years of experience with first generatio...

2024-10-03 22:15 1731

WELLlife COVID-19/Influenza A&B Home Test on Sale for Amazon Prime Day

Standfirst: Welllife, a Flu home test in addition to COVID-19 BOLINGBROOK, Ill., Oct. 3, 2024 /PRNewswire/ -- WELLlife, a leading innovator in medical diagnostic and testing solutions, is increasing accessibility to respiratory illness testing this flu season. The WELLlife COVID-19/Influenza A&B...

2024-10-03 21:00 1175

Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

-  Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 /PRNewswire/ -- Hetero, India's leading pharmaceutical comp...

2024-10-02 22:53 2511

OPTEL and Worximity Join Forces to Boost Line Performance with Real-Time OEE Solutions

QUÉBEC CITY, Oct. 1, 2024 /PRNewswire/ -- OPTEL, a global leader in traceability and vision systems, and Worximity, a leading provider of OEE and real-time production monitoring, are partnering to help manufacturers boost operational efficiency.

2024-10-01 19:00 1085

Frost & Sullivan co-published Recombinant Type III Triple-Helix Collagen Whitepaper with Everon Healthcare

SHANGHAI, Oct. 1, 2024 /PRNewswire/ -- Frost & Sullivan and Everon Healthcare have conducted extensive investigation across the recombinant collagen Industry and co-published the "Recombinant Type III Triple-Helix Collagen Whitepaper" on Sep. 29th, 2024, which aims to analyze the latest research a...

2024-10-01 17:28 1843

TraceLink Releases Amadeus, the First Generative AI Assistant for Accelerating the Digitalization of Supply Networks on the Opus Platform

Trained on a rich set of information from a unified content repository, Opus Orchestration Architects, Solution Designers, Network Administrators, and those simply interested in learning more about TraceLink's solutions are empowered with information in seconds BOSTON, Oct. 1, 2024 /PRNewswire/ ...

2024-10-01 16:00 1371

Great Place To Work® Australia and New Zealand names 15 Best Workplaces in Healthcare, Biopharma & Social Assistance in 2024

SYDNEY, Oct. 1, 2024 /PRNewswire/ -- Great Place To Work® ANZ, the global authority on workplace culture today announces theirinaugural 15 Best Workplaces™ in Healthcare, Social Assistance and BioPharma in 2024.   The companies are announced across two lists: Best Workplaces in Biotechnology a...

2024-10-01 07:00 8048

Doer Biologics Announces First Patient Dosed in Phase 2 Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, Sept. 30, 2024 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeti...

2024-09-30 15:00 1064
1 ... 891011121314 ... 313

Week's Top Stories